Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone.
Bloch
Michael J
MJ
Division of General Internal Medicine, University of Nevada School of Medicine, Reno, NV, USA. mbloch@aol.com
Basile
Jan
J